Pressure-Enabled Drug Delivery (Pedd) of a Class C TLR9 Agonist in Combination With Checkpoint Inhibitor Therapy in a Pancreatic Cancer Murine Model

被引：0
|
作者：
Vicente, Diego [1 ]
Capacio, Benedict [1 ]
Narayanan, Jayanth Shankara [1 ]
Liu, Yujia [2 ]
LaPorte, Jason [2 ]
Cox, Bryan [2 ]
Jaroch, David [2 ]
Katz, Steven [2 ]
White, Rebekah [1 ]
机构：
[1] Univ Calif San Diego, San Diego, CA USA
[2] TriSalus Life Sci, Westminster, CO USA
来源：
ANNALS OF SURGICAL ONCOLOGY | 2023年 / 30卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
E156
引用
收藏
页码：S110 / S110
页数：1
相关论文
共 9 条
  • [1] Pressure-Enabled Drug Delivery (PEDD) of a class C TLR9 agonist in combination with checkpoint inhibitor therapy in a murine pancreatic cancer model
    Capacio, Benedict A.
    Narayanan, Jayanth S. Shankara
    Vicente, Diego A.
    Liu, Yujia
    LaPorte, Jason P.
    Cox, Bryan F.
    Jaroch, David B.
    Katz, Steven C.
    White, Rebekah R.
    SURGERY, 2023, 174 (03) : 666 - 673
  • [2] Pressure-Enabled Drug Delivery (PEDD) of a class C TLR9 agonist in combination with checkpoint inhibitor therapy in a murine pancreatic cancer model.
    Capacio, Benedict
    Narayanan, Jayanth Shankara
    Vicente, Diego
    Liu, Yujia
    LaPorte, Jason
    Cox, Bryan
    Jaroch, David
    Katz, Steven
    White, Rebekah Ruth
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 729 - 729
  • [3] Safety and early biologic effects of phase 1 PERIO-01 trial of pressure-enabled drug delivery (PEDD) of TLR9 agonist SD-101 and immune checkpoint inhibition (ICI) in uveal melanoma metastatic to the liver (MUM)
    Montazeri, Kamaneh
    Davar, Diwakar
    Haymaker, Cara L.
    Sheth, Rahul
    Kuban, Joshua
    Weintraub, Joshua
    Wehrenberg-Klee, Eric
    Novelli, Paula M.
    Gonsalves, Carin F.
    Adamo, Robert D.
    Lucci, Anthony
    Meas, Salyna
    Sarli, Vanessa Nicole
    Prieto, Victor Gerardo
    Geller, David A.
    Orloff, Marlana M.
    Carvajal, Richard D.
    Patel, Sapna Pradyuman
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] PERIO-01: Initial safety experience and immunologic effects of a Class C TLR9 agonist using pressure-enabled drug delivery in a phase 1 trial of hepatic arterial infusion of SD-101+/- checkpoint inhibition in metastatic uveal melanoma
    Patel, Sapna P.
    Haymaker, Cara
    Sheth, Rahul A.
    Kuban, Joshua D.
    Weintraub, Joshua
    Wehrenberg-Klee, Eric
    Novelli, Paula
    Gonsalves, Carin
    Adamo, Robert
    Honaker, Virgina
    Timciuc, Laura
    Hennegan, Tarin
    Molina, Juan C. Amador
    Duose, Dzifa
    Cuenta, Edwin R. Parras
    Lucci, Anthony
    Meas, Salyna
    Sarli, Vanessa
    Prieto, Victor G.
    LaPorte, Jason
    Hulstine, Ann-Marie
    Moody, Ashley
    Cox, Bryan
    Geller, David
    Davar, Diwakar
    Montazeri, Kamaneh
    Orloff, Marlana
    Katz, Steven C.
    Carvajal, Richard
    CANCER RESEARCH, 2023, 83 (07)
  • [5] Impact of Toll-Like Receptor 9 Agonist Class on Immunologic Effects in a Model of Liver Metastases with Pressure-Enabled Drug Delivery Regional infusion
    Cournoyer, Lauren
    Ghosh, Chandra C.
    Liu, Yujia
    Ballarin, Alizee
    Laporte, Jason
    Guha, Prajna
    Cox, Bryan F.
    Katz, Steven C.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2023, 237 (05) : S472 - S473
  • [6] Combination Radiation Therapy and Selective TLR9 Agonist Improves Local Control in a Murine Model of HPV-Related HNSCC
    Kim, S.
    Sumner, W.
    Miyauchi, S.
    Mell, L. K.
    Califano, J. A.
    Sharabi, A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : S41 - S42
  • [7] Impact of Pressure-Enabled Drug Delivery (PEDD) of Nelitolimod (SD-101) into the Liver with Systemic Immune Checkpoint Inhibitor (ICI) for Treating Metastatic Uveal Melanoma with Liver Metastases (MUM-LM)
    Layman, Ilan
    Ghosh, Chandra C.
    Cournoyer, Lauren
    Guha, Prajna
    Laporte, Jason
    Ballarin, Alizee
    Morrissey, Molly
    Fraser, Kayla M.
    Cox, Bryan F.
    Katz, Steven C.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2024, 239 (05) : S446 - S446
  • [8] COMBINATION THERAPY WITH A HYPOMETHYLATING DRUG (DECITABINE) PLUS AN IMMUNE CHECKPOINT INHIBITOR (ANTI-PD-1H) IN THE KPC MOUSE MODEL OF PANCREATIC CANCER
    Gonda, Tamas A.
    Tycko, Benjamin
    Salas, Martha C.
    Do, Catherine
    Fang, Jarwei
    Olive, Kenneth P.
    GASTROENTEROLOGY, 2017, 152 (05) : S42 - S43
  • [9] PERIO-02: Phase 1b pressure enabled regional immuno-oncology trial of nelitolimod (SD-101), a class C TLR9 agonist, delivered via hepatic artery infusion plus /-checkpoint inhibition in intrahepatic cholangiocarcinoma and hepatocellular carcinoma.
    Lee, Sunyoung S.
    Almhanna, Khaldoun
    Sheth, Rahul
    Pant, Shubham
    Kuban, Joshua
    Maxwell, Aaron Wilhelm Palmer
    Witt, Brian Justin
    LaPorte, Jason
    Hulstine, Ann-Marie
    Cox, Bryan
    Carvajal, Richard D.
    White, Ruth Aroon
    Weintraub, Joshua
    Davis, Lindsey
    Hart, James
    Knight, Robert D.
    Katz, Steven C.
    Javle, Milind M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
1